Sugammadex for Reversal of Neuromuscular Blockade in a Patient With Renal Failure
- PMID: 31093024
- PMCID: PMC6510526
- DOI: 10.5863/1551-6776-24.3.238
Sugammadex for Reversal of Neuromuscular Blockade in a Patient With Renal Failure
Abstract
Residual neuromuscular blockade following the use of non-depolarizing neuromuscular blocking agents (NMBAs) can lead to postoperative respiratory complications, including oxygen desaturation, atelectasis, and pneumonia. Sugammadex rapidly reverses steroidal NMBAs by encapsulating them in a highly stable water-soluble complex. This NMBA-sugammadex complex then undergoes renal elimination. In patients with renal insufficiency or failure, concern has been expressed regarding the elimination of the NMBA-sugammadex complex. We present a 19-year-old patient with renal failure who received sugammadex for reversal of neuromuscular blockade. The use of sugammadex in patients with renal dysfunction is discussed and safety concerns are reviewed.
Keywords: neuromuscular blockade; renal failure; reversal; sugammadex.
References
-
- Tobias JD. Current evidence for the use of sugammadex in children. Paediatr Anaesth. 2017;27(2):118–125. - PubMed
-
- Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesth Analg. 2010;111(1):120–128. - PubMed
-
- Eikermann M, Vogt FM, Herbstreit F et al. The predisposition to inspiratory upper airway collapse during partial neuromuscular blockade. Am J Respir Crit Care Med. 2007;175(1):9–15. - PubMed
Publication types
LinkOut - more resources
Full Text Sources